Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer

Ann H. Partridge, Kathryn J. Ruddy, Shari Gelber, Lidia Schapira, Mary Abusief, Meghan Meyer, Elizabeth Ginsburg

Research output: Contribution to journalArticlepeer-review

141 Scopus citations

Abstract

Objective: To compare markers of ovarian reserve between women exposed to cytotoxic chemotherapy for early stage breast cancer and matched controls. Design: Cross-sectional evaluation of markers of ovarian reserve. Setting: Dana-Farber/Brigham and Women's Cancer Center, Massachusetts General Hospital, and Faulkner Hospital in Boston, MA. Patient(s): Breast cancer survivors with continued menses after chemotherapy were compared with age-matched, gravidity-matched controls. Main Outcome Measure(s): Antral follicle count (AFC), anti-Müllerian hormone (AMH), FSH, inhibin B (InB), and E2 on day 2, 3, or 4 of the menstrual cycle. A Bonferroni correction was performed to correct for multiple comparisons. Result(s): Twenty survivors and 20 controls were evaluated; 50% of survivors were currently on tamoxifen. Median AFC was 6 for survivors and 9.5 for controls. There were significant differences between the two groups in AFC, AMH, and nonsignificant differences in FSH and InB, all indicating better ovarian reserve in controls. The AFC and AMH levels were highly correlated (r = 0.72). Survivors on tamoxifen had lower AFC, AMH, InB, and higher E2 than nontamoxifen-treated survivors. Conclusion(s): Premenopausal breast cancer survivors have diminished ovarian reserve compared with controls.

Original languageEnglish (US)
Pages (from-to)638-644
Number of pages7
JournalFertility and sterility
Volume94
Issue number2
DOIs
StatePublished - Jul 2010

Keywords

  • Ovarian reserve
  • breast cancer
  • chemotherapy
  • fertility
  • premenopausal

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Fingerprint

Dive into the research topics of 'Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer'. Together they form a unique fingerprint.

Cite this